HER2-Positive Breast Cancer | Clinical

November 15, 2022

Erika P. Hamilton, MD, discusses the purpose of a safety follow-up analysis for the DESTINY-Breast03 trial of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

October 20, 2022

TAC01-HER2 elicited encouraging safety and clinical activity in patients with HER2-positive solid tumors with no dose limiting toxicities, cytokine release syndrome, or immune effector cell-associated neurotoxicity observed.

October 14, 2022

William J. Gradishar, MD, discusses the choice of adjuvant or neoadjuvant regimens for patients with HER2-positive breast cancer.

October 13, 2022

During a Targeted Oncology case-based roundtable event, Jennifer M. Matro, MD, discussed the data supporting systemic therapies for treatment of early-stage HER2-positive breast cancer including trastuzumab and pertuzumab.

September 24, 2022

Pertuzumab plus trastuzumab and chemotherapy remains the standard of care for HER2-positive breast cancer, after the addition of atezolizumab did not benefit responses in the Impassion050 study.

September 16, 2022

In season 3, episode 8 of Targeted Talks, Christie J. Hilton, DO, discusses treating first- and second-line HER2-positive breast cancer.

September 14, 2022

Rachel Wuerstein, MD, discusses the KAMILLA trial of trastuzumab emtansine in metastatic breast cancer for both a global and Asian cohort.

September 10, 2022

Adding abemaciclib to trastuzumab improved overall survival in women with with hormone receptor–positive, HER2-positive advanced breast cancer, according to new findings discussed at the 2022 ESMO Congress.

August 16, 2022

Erika P. Hamilton, MD, discusses how researchers are addressing unmet needs for patients with HER2-positive breast cancer.

August 15, 2022

Findings from the phase 2 DESTINY-Breast02 show that trastuzumab deruxtecan improves both progression-free and overall survival in patients with HER2-positive unresectable and/or metastatic breast cancer.